Delving into the Latest Updates on Vamifeport hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Vamifeport

Target

FPN1

Mechanism

FPN1 inhibitors(Ferroportin-1 inhibitors)

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesCongenital Disorders+ [3]

Active Indication

Beta-ThalassemiaSystemic Carnitine DeficiencyAnemia, Sickle Cell

Inactive Indication

Non-transfusion dependent thalassaemiaTransfusion-dependent Beta Thalassemia

Originator Organization

Vifor Pharma AG

Active Organization

Vifor (International) AGVifor Fresenius Medical Care Renal Pharma France S.A.S.

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC21H21FN6O2

InChIKeyKNYVRFXIVWUGBZ-UHFFFAOYSA-N

CAS Registry2095668-10-1

Two different vamifeport oral formulations will be administered in fed and fasted state to assess the vamifeport food-drug interaction and to assess the relative bioavailability (the proportion of drug entering the circulation) of 2 different vamifeport oral formulations in healthy adult participants.
Participants will be randomly allocated to one of four treatment sequences, with four dosing periods each, where different combinations of both formulations will be administered following fasted and fed state.
The total study duration for each participant is up to 7 weeks and 4 days.

Start Date14 Oct 2021

Sponsor / Collaborator

Vifor (International) AG

NCT04938635 / WithdrawnPhase 2

A Phase 2b, Double-blind, Randomised, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of VIT-2763 Multiple Doses in Adults With Transfusion-dependent Beta-thalassaemia

The main purpose of this study is to evaluate the efficacy of 3 multiple doses of VIT-2763 as measured by the reduction in red blood cell (RBC) transfusion burden from Week 13 to Week 24, to identify the most efficacious and safe dose.

Start Date20 Sep 2021

Sponsor / Collaborator

Vifor (International) AG

[+1]

NCT04817670 / CompletedPhase 2

A Phase 2a, Double-blind, Randomised, Placebo-controlled, Efficacy, and Safety Study of Multiple Doses of VIT-2763 in Subjects With Sickle Cell Disease

The purpose of this study is to investigate the effect of VIT-2763 on markers of hemolysis (breakdown in red blood cells) in sickle cell disease (SCD). The safety, tolerability and clinical beneficial effects of VIT-2763 for the treatment of SCD are also explored.

Start Date18 Jun 2021

Sponsor / Collaborator

Vifor (International) AG

[+1]

100 Clinical Results associated with Vamifeport hydrochloride

Login to view more data

100 Translational Medicine associated with Vamifeport hydrochloride

Login to view more data

100 Patents (Medical) associated with Vamifeport hydrochloride

Login to view more data

13

Literatures (Medical) associated with Vamifeport hydrochloride

01 Sep 2024·HemaSphere

The oral ferroportin inhibitor vamifeport prevents liver iron overload in a mouse model of hemochromatosis

Article

Author: Altermatt, Patrick ; Flace, Anna ; Nyffenegger, Naja ; Sundstrom, Hanna ; Manolova, Vania ; Varol, Ahmet ; Doucerain, Cédric ; Dürrenberger, Franz

AbstractHemochromatosis is an inherited iron overload condition caused by mutations that reduce the levels of the iron‐regulatory hormone hepcidin or its binding to ferroportin. The hepcidin–ferroportin axis is pivotal to iron homeostasis, providing opportunities for therapeutic intervention in iron overload disorders like hemochromatosis. The aim of this study was to evaluate the efficacy of the oral ferroportin inhibitor vamifeport in the Hfe C282Y mouse model, which carries the most common mutation found in patients with hemochromatosis. A single oral dose of vamifeport lowered serum iron levels in Hfe C282Y mice, with delayed onset and shorter duration than observed in wild‐type mice. Vamifeport induced transient hypoferremia by inhibiting ferroportin and resulted in a feedback regulation of liver Hamp in wild‐type mice, which was absent in Hfe C282Y mice, reflecting the dysregulated systemic iron sensing in this hemochromatosis model. Chronic dosing with vamifeport led to sustained serum and liver iron reductions in Hfe C282Y mice, as well as markedly reducing liver Hamp expression in Hfe C282Y mice, suggesting distinct regulation of liver Hamp expression following acute or continuous iron restriction via vamifeport. At the tested dose, vamifeport retained its activity when combined with phlebotomy and did not significantly interfere with liver iron removal by phlebotomy in Hfe C282Y mice. These data demonstrate that chronic vamifeport treatment significantly reduces serum iron levels and prevents liver iron loading in the Hfe C282Y mouse model of hemochromatosis, thus providing preclinical proof of concept for the efficacy of vamifeport in hemochromatosis with or without phlebotomy.

01 Oct 2023·Haematologica

Ferroportin inhibitor vamifeport ameliorates ineffective erythropoiesis in a mouse model of β-thalassemia with blood transfusions.

Article

Author: Altermatt, Patrick ; Nyffenegger, Naja ; Flace, Anna ; Dürrenberger, Franz ; Kalleda, Natarajaswamy ; Doucerain, Cédric ; Ingoglia, Giada ; Manolova, Vania

β-thalassemia is an inherited anemia characterized by ineffective erythropoiesis. Blood transfusions are required for survival in transfusion-dependent β-thalassemia and are also occasionally needed in patients with non-transfusion-dependent β-thalassemia. Patients with transfusion-dependent b-thalassemia often have elevated transferrin saturation (TSAT) and non-transferrin-bound iron (NTBI) levels, which can lead to organ iron overload, oxidative stress, and vascular damage. Vamifeport is an oral ferroportin inhibitor that was previously shown to ameliorate anemia, ineffective erythropoiesis, and dysregulated iron homeostasis in the Hbbth3/+ mouse model of β-thalassemia, under non-transfused conditions. Our study aimed to assess the effects of oral vamifeport on iron-related parameters (including plasma NTBI levels) and ineffective erythropoiesis following blood transfusions in Hbbth3/+ mice. A single dose of vamifeport prevented the transient transfusion-mediated NTBI increase in Hbbth3/+ mice. Compared with vehicle treatment, vamifeport significantly increased hemoglobin levels and red blood cell counts in transfused mice. Vamifeport treatment also significantly improved ineffective erythropoiesis in the spleens of Hbbth3/+ mice, with additive effects observed when treatment was combined with repeated transfusions. Vamifeport corrected leukocyte counts and significantly improved iron-related parameters (serum transferrin, TSAT and erythropoietin levels) versus vehicle treatment in Hbbth3/+ mice, irrespective of transfusion status. In summary, vamifeport prevented transfusion-mediated NTBI formation in Hbbth3/+ mice. When given alone or combined with blood transfusions, vamifeport also ameliorated anemia, ineffective erythropoiesis, and dysregulated iron homeostasis. Administering vamifeport together with repeated blood transfusions additively ameliorated anemia and ineffective erythropoiesis in this mouse model, providing preclinical proof-of-concept for the efficacy of combining vamifeport with blood transfusions in β-thalassemia.

18 Aug 2022·Blood

The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease

Article

Author: Doucerain, Cédric ; Flace, Anna ; Dürrenberger, Franz ; Buehler, Paul W. ; Nyffenegger, Naja ; Zennadi, Rahima ; Ingoglia, Giada ; Kalleda, Natarajaswamy ; Manolova, Vania ; Buzzi, Raphael M. ; Schaer, Dominik J.

AbstractSickle cell disease (SCD) is an inherited hemolytic anemia caused by a single point mutation in the β-globin gene of hemoglobin that leads to synthesis of sickle hemoglobin (HbS) in red blood cells (RBCs). HbS polymerizes in hypoxic conditions, leading to intravascular hemolysis, release of free hemoglobin and heme, and increased adhesion of blood cells to the endothelial vasculature, which causes painful vaso-occlusion and organ damage. HbS polymerization kinetics are strongly dependent on the intracellular HbS concentration; a relatively small reduction in cellular HbS concentration may prevent HbS polymerization and its sequelae. We hypothesized that iron restriction via blocking ferroportin, the unique iron transporter in mammals, might reduce HbS concentration in RBCs, thereby decreasing hemolysis, improving blood flow, and preventing vaso-occlusive events. Indeed, vamifeport (also known as VIT-2763), a clinical-stage oral ferroportin inhibitor, reduced hemolysis markers in the Townes model of SCD. The RBC indices of vamifeport-treated male and female Townes mice exhibited changes attributable to iron-restricted erythropoiesis: decreased corpuscular hemoglobin concentration mean and mean corpuscular volume, as well as increased hypochromic and microcytic RBC fractions. Furthermore, vamifeport reduced plasma soluble VCAM-1 concentrations, which suggests lowered vascular inflammation. Accordingly, intravital video microscopy of fluorescently labeled blood cells in the microvasculature of Townes mice treated with vamifeport revealed diminished adhesion to the endothelium and improved hemodynamics. These preclinical data provide a strong proof-of-concept for vamifeport in the Townes model of SCD and support further development of this compound as a potential novel therapy in SCD.

100 Deals associated with Vamifeport hydrochloride

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Beta-Thalassemia	Discovery	GR	Vifor (International) AG	11 Jun 2020
Beta-Thalassemia	Discovery	IL	Vifor (International) AG	11 Jun 2020
Beta-Thalassemia	Discovery	TH	Vifor (International) AG	11 Jun 2020
Beta-Thalassemia	Discovery	LB	Vifor (International) AG	11 Jun 2020
Beta-Thalassemia	Discovery	IT	Vifor (International) AG	11 Jun 2020
Beta-Thalassemia	Discovery	IL	Vifor (International) AG	11 Jun 2020
Beta-Thalassemia	Discovery	GR	Vifor (International) AG	11 Jun 2020
Beta-Thalassemia	Discovery	IT	Vifor (International) AG	11 Jun 2020
Beta-Thalassemia	Discovery	TH	Vifor (International) AG	11 Jun 2020
Beta-Thalassemia	Discovery	LB	Vifor (International) AG	11 Jun 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04364269 (VITHAL, CTgov)	Phase 2	Beta-Thalassemia \| Non-transfusion dependent thalassaemia	35	Placebo	tmidqryors(bryqtjasrv) = awyvjglnih euxjwhwavs (fmybnhnqdl, mbqibojfdl - actqhszrpn) View more	-	14 Dec 2023
NCT04364269 (EHA2022) Manual	Phase 2	Transfusion-dependent Beta Thalassemia	25	Vamifeport hydrochloride (QD)	(wchttyiozt) = ufxzruhlda lornzqacmt (vvebwrbbab ) View more	Positive	12 May 2022
NCT04364269 (EHA2022) Manual	Phase 2	Transfusion-dependent Beta Thalassemia	25	Vamifeport hydrochloride (BID)	(xofiabhzgk) = nwrmrckugi wqhtwbvlgy (rbedcegjel ) View more	Positive	12 May 2022